Literature DB >> 25309075

Stool characteristics of infants receiving short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides: a review.

Petra A M J Scholtens1, Dominique A M Goossens1, Annamaria Staiano1.   

Abstract

Human milk is considered to be the optimal source of infant nutrition. Some of the benefits of breastfeeding have been ascribed to human milk oligosaccharides (HMO). For instance, HMO can affect faecal characteristics such as stool consistency and stool frequency. Such effects on stool characteristics can be beneficial for young infants as hard stools and even constipation is common in that age group. Prebiotics in infant milk formulas have been introduced to exert similar functionalities. A specific mixture of prebiotics consists of a combination of short chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS) in a ratio of 9:1. This specific mixture has been developed to closely resemble the molecular size composition of HMO. Many studies have been done with scGOS/lcFOS, and indicators for digestive comfort have often been included as secondary outcomes. This review summarizes the effects of scGOS/lcFOS (9:1) on stool consistency, stool frequency and transit time in healthy term and preterm infants. In several of the studies with scGOS/lcFOS in a ratio of 9:1 in infant milk formulas, positive effects of this mixture on stool characteristics such as stool consistency and stool frequency were observed. As stool consistency was shown to be correlated to whole gut transit time, scGOS/lcFOS can be hypothesised to have a role in reducing the risk of constipation.

Entities:  

Keywords:  Infants; Long-chain fructooligosaccharides; Short-chain galactooligosaccharides; Stool consistency; Stool frequency

Mesh:

Substances:

Year:  2014        PMID: 25309075      PMCID: PMC4188896          DOI: 10.3748/wjg.v20.i37.13446

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  49 in total

1.  Diagnosis and management in children with severe and protracted constipation and obstipation.

Authors:  M DAVIDSON; M M KUGLER; C H BAUER
Journal:  J Pediatr       Date:  1963-02       Impact factor: 4.406

Review 2.  Review article: prebiotics in the gastrointestinal tract.

Authors:  S Macfarlane; G T Macfarlane; J H Cummings
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

3.  The effect of a prebiotic supplemented formula on growth and stool microbiology of term infants.

Authors:  C Costalos; A Kapiki; M Apostolou; E Papathoma
Journal:  Early Hum Dev       Date:  2007-04-11       Impact factor: 2.079

4.  Bifidogenic effects of solid weaning foods with added prebiotic oligosaccharides: a randomised controlled clinical trial.

Authors:  Petra A M J Scholtens; Martine S Alles; Jacques G Bindels; Esmeralda G M van der Linde; Jules J M Tolboom; Jan Knol
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-05       Impact factor: 2.839

Review 5.  Introducing inulin-type fructans.

Authors:  Marcel B Roberfroid
Journal:  Br J Nutr       Date:  2005-04       Impact factor: 3.718

6.  Prebiotic concept for infant nutrition.

Authors:  G Boehm; S Fanaro; J Jelinek; B Stahl; A Marini
Journal:  Acta Paediatr Suppl       Date:  2003-09

7.  Total and segmental colonic transit time and anorectal manometry in children with chronic idiopathic constipation.

Authors:  Carolina Gutiérrez; Alfredo Marco; Angel Nogales; Roque Tebar
Journal:  J Pediatr Gastroenterol Nutr       Date:  2002-07       Impact factor: 2.839

8.  Fructooligosaccharides exhibit more rapid fermentation than long-chain inulin in an in vitro fermentation system.

Authors:  Maria L Stewart; Derek A Timm; Joanne L Slavin
Journal:  Nutr Res       Date:  2008-05       Impact factor: 3.315

9.  Precipitants of constipation during early childhood.

Authors:  Stephen M Borowitz; Daniel J Cox; Anita Tam; Lee M Ritterband; James L Sutphen; J Kim Penberthy
Journal:  J Am Board Fam Pract       Date:  2003 May-Jun

10.  Oligosaccharides from human milk as revealed by matrix-assisted laser desorption/ionization mass spectrometry.

Authors:  B Stahl; S Thurl; J Zeng; M Karas; F Hillenkamp; M Steup; G Sawatzki
Journal:  Anal Biochem       Date:  1994-12       Impact factor: 3.365

View more
  17 in total

1.  Partly Fermented Infant Formulae With Specific Oligosaccharides Support Adequate Infant Growth and Are Well-Tolerated.

Authors:  Frédéric Huet; Marieke Abrahamse-Berkeveld; Sebastian Tims; Umberto Simeoni; Gérard Beley; Christoph Savagner; Yvan Vandenplas; Jonathan O'B Hourihane
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-10       Impact factor: 2.839

2.  Randomised controlled trial demonstrates that fermented infant formula with short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides reduces the incidence of infantile colic.

Authors:  Yvan Vandenplas; Thomas Ludwig; Hetty Bouritius; Philippe Alliet; Derek Forde; Stefaan Peeters; Frederic Huet; Jonathan Hourihane
Journal:  Acta Paediatr       Date:  2017-04-19       Impact factor: 2.299

3.  Promising Effects of Neurorestorative Diets on Motor, Cognitive, and Gastrointestinal Dysfunction after Symptom Development in a Mouse Model of Parkinson's Disease.

Authors:  Paula Perez-Pardo; Esther M de Jong; Laus M Broersen; Nick van Wijk; Amos Attali; Johan Garssen; Aletta D Kraneveld
Journal:  Front Aging Neurosci       Date:  2017-03-20       Impact factor: 5.750

4.  Bifidobacterium mongoliense genome seems particularly adapted to milk oligosaccharide digestion leading to production of antivirulent metabolites.

Authors:  Pauline Bondue; Christian Milani; Emilie Arnould; Marco Ventura; Georges Daube; Gisèle LaPointe; Véronique Delcenserie
Journal:  BMC Microbiol       Date:  2020-05-07       Impact factor: 3.605

5.  An infant formula with large, milk phospholipid-coated lipid droplets containing a mixture of dairy and vegetable lipids supports adequate growth and is well tolerated in healthy, term infants.

Authors:  Laura M Breij; Marieke Abrahamse-Berkeveld; Yvan Vandenplas; Sabine N J Jespers; Amerik C de Mol; Poh Choo Khoo; Masendu Kalenga; Stefaan Peeters; Ron H T van Beek; Obbe F Norbruis; Stefanie Schoen; Dennis Acton; Anita C S Hokken-Koelega
Journal:  Am J Clin Nutr       Date:  2019-03-01       Impact factor: 7.045

6.  The Magnesium-Rich Formula for Functional Constipation in Infants: a Randomized Comparator-Controlled Study.

Authors:  Marc A Benninga; Yvan Vandenplas
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2019-04-18

7.  A Partly Fermented Infant Formula with Postbiotics Including 3'-GL, Specific Oligosaccharides, 2'-FL, and Milk Fat Supports Adequate Growth, Is Safe and Well-Tolerated in Healthy Term Infants: A Double-Blind, Randomised, Controlled, Multi-Country Trial.

Authors:  Yvan Vandenplas; Virginie de Halleux; Małgorzata Arciszewska; Piotr Lach; Valeriy Pokhylko; Viktoriia Klymenko; Stefanie Schoen; Marieke Abrahamse-Berkeveld; Kelly A Mulder; Rocio Porcel Rubio
Journal:  Nutrients       Date:  2020-11-20       Impact factor: 5.717

8.  Genome of Bifidobacteria and Carbohydrate Metabolism.

Authors:  Pauline Bondue; Véronique Delcenserie
Journal:  Korean J Food Sci Anim Resour       Date:  2015-02-28       Impact factor: 2.622

9.  Cell-Free Spent Media Obtained from Bifidobacterium bifidum and Bifidobacterium crudilactis Grown in Media Supplemented with 3'-Sialyllactose Modulate Virulence Gene Expression in Escherichia coli O157:H7 and Salmonella Typhimurium.

Authors:  Pauline Bondue; Sébastien Crèvecoeur; François Brose; Georges Daube; Marie-Christine Seghaye; Mansel W Griffiths; Gisèle LaPointe; Véronique Delcenserie
Journal:  Front Microbiol       Date:  2016-09-22       Impact factor: 5.640

10.  Randomized, Double-Blind, Placebo-Controlled Parallel Clinical Trial Assessing the Effect of Fructooligosaccharides in Infants with Constipation.

Authors:  Daniela da Silva Souza; Soraia Tahan; Thabata Koester Weber; Humberto Bezerra de Araujo-Filho; Mauro Batista de Morais
Journal:  Nutrients       Date:  2018-11-01       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.